SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels Q3 results were overshadowed by weaker-than-expected Q4 guidance, persistent PC demand weakness, and manufacturing constraints, prompting analyst downgrades. Traders are divided between viewing the selloff as an overreaction and warning that the outlook points to a longer, more difficult recovery.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisks strong quarterly results and raised outlook failed to prevent a sharp selloff alongside other chip and AI stocks, prompting debate over profit-taking and whether NAND pricing and earnings growth may be nearing a cyclical peak. Many traders call the drop an overreaction and point to AI-driven data-center demand, while others worry about valuation and the memory cycle; the company also announced an eight-for-one stock split.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly earnings miss and heavy AI infrastructure spending have intensified concerns about negative free cash flow and whether the investment will generate sufficient returns, weighing on the shares. Traders are divided: some see the selloff as overdone given accelerating AWS growth, while others argue that cloud growth does not yet justify the spending.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits shares sold off after a strong quarterly report was overshadowed by softer revenue guidance, slowing user growth, declining search referrals, and plans to test a logged-in-only experience. Traders worry the changes could further reduce traffic, while some view the drop as an overreaction to otherwise strong results.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Reports of a major Binance security breach are driving Bitcoins pullback and renewed concerns about exchange security and crypto custody. Traders are split between warning of broader fallout and arguing the breach involved an exchange, not Bitcoins protocol, with some viewing the dip as a buying opportunity.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

SLV is drawing attention for a sharp, persistent silver selloff after its earlier surge, with traders focused on the break below $50 and where support may emerge. Bearish posts warn of further losses, while dip buyers point to oversold conditions and physical-metal demand; claims of deliberate price suppression remain speculation.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbases quarterly results are drawing scrutiny despite a headline profit beat: traders point to softer underlying operating performance and crypto-related valuation gains behind much of the reported profit. A reported multibillion-dollar Binance breach and weakness in crypto prices have added pressure, with debate over whether Coinbase could benefit as a rival exchange or face broader confidence risks.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure amid a technology selloff following Amazons heavy AI-spending and cash-flow concerns and Intels weak outlook, reviving questions about whether Big Techs capital investments will generate sufficient returns. Traders are split between calling the move an AI-bubble warning and viewing the pullback as a buying opportunity.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias unexpectedly timed third-quarter results are driving discussion, with traders highlighting year-over-year LUPKYNIS sales growth, higher full-year revenue guidance and a substantial cash balance. Reactions are mixed: some call the report solid, while others question the lack of a conference call, muted share-price response and whether cash will be used for buybacks or pipeline development.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians quarterly results beat expectations and the company raised its delivery outlook, with traders pointing to the R2 ramp as a growth driver. The upbeat reaction is tempered by concerns over cash burn and profitability, as some traders are disappointed that the shares have given back gains amid a weak broader market.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Equity

Under the FDA’s new draft guidance, companies can file one application that covers several versions of the same gene-editing treatment, as long as each version aims to make the same kind of genetic correction.


EDIT Set to Begin First-in-Human Study in Hypercholesterolemia 

Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.

Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027

In studies on non-human primates, EDIT-401 reduced bad cholesterol and other harmful blood fats by around 90%.


CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.

TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday

U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.read more...

This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.read more...

Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.

Editas Medicine Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Companies with modular gene editing platforms stand to benefit most, including Prime Medicine’s prime-editing system and lipid-nanoparticle delivery, if the draft is adopted.</li><li>The draft guidance is now open for public comment, which will later be reviewed by the FDA before it decides whether to adopt it.&nbsp;</li><li>Earlier this month, the company announced it had dosed the first patient in a global Phase 1/2 trial of PM577a for Wilson disease—the first known use of prime editing therapy inside a living patient.</li></ul>Shares of gene-editing companies, including Prime Medicine (PRME), rallied on Wednesday after the U.S. Food and Drug Administration issued draft guidance designed to speed personalized treatment for rare genetic diseases.Under the FDA’s new draft guidance, companies can file one application that covers several versions of the same gene-editing treatment, as long as each version aims to make the same kind of genetic correction. Once clinical results support the core approach, new versions that stay within set limits can be added later using mainly lab tests instead of full new patient trials. The guidance applies to gene-editing therapies for rare diseases caused by a single known genetic fault.Companies with modular gene editing platforms stand to benefit most, including Prime Medicine’s prime-editing system and lipid-nanoparticle delivery, if the draft is adopted. The draft guidance is now open for public comment, which will be later reviewed by the FDA before it decides whether to adopt it.Shares of Prime Medicine were up 20% at the time of writing, while Beam Therapeutics traded 14% higher and Intellia Therapeutics (NTLA) and Editas Medicine (EDIT) climbed 6-11%. CRISPR Therapeutics (CRSP) posted more modest gains of 4%.<h2 class="st-heading-2">Why PRME Is Outperforming Peers</h2>Prime clocked larger gains than its peers as it builds on company-specific updates. Earlier this month, the company announced it had dosed the first patient in a global Phase 1/2 trial of PM577a for Wilson disease—the first known use of prime editing therapy inside a living patient. The FDA also granted the program Rare Pediatric Disease designation. Initial clinical data from the Wilson disease study are expected in 2027.The company also recently received the FDA’s clearance to start human trials of an alpha-1 antitrypsin deficiency candidate.<h2 class="st-heading-2">How Did PRME Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$PRME" data-symbol-id="PRME" href="https://stocktwits.com/symbol/PRME" target="_blank">PRME stock</a> jumped from 'neutral' to 'extremely bullish' territory over the past 24 hours, while message volume increased from 'low' to 'extremely high' levels.A Stocktwits user noted that big pharma company Bristol Myers Squibb is invested in Prime. The user is referring to a collaboration deal between BMY and Prime inked in Sept. 2024 under which Prime received $110 million upfront, including a $55 million equity investment. The company is eligible for more than $3.5 billion in potential milestones under the deal.<stembedurl>https://stocktwits.com/Cello69/message/667555201</stembedurl>Another user, however, warned of upcoming dilution.<stembedurl>https://stocktwits.com/Regard994/message/667538755</stembedurl>PRME stock has gained 51% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/uber-stock-hits-fresh-52-week-low-ahead-of-earnings-as-robotaxi-fears-linger/cZU9V5OR9GK">UBER Stock Hits Fresh 52-Week Low Ahead Of Earnings As Robotaxi Fears Linger</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artwork of DNA Editing. Source: Getty Images

Under the FDA’s new draft guidance, companies can file one application that covers several versions of the same gene-editing treatment, as long as each version aims to make the same kind of genetic correction.

Beam Therapeutics Inc

CRISPR Therapeutics AG

Intellia Therapeutics Inc

Prime Medicine Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

EDIT News